Patents by Inventor Patrick Harran

Patrick Harran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10544131
    Abstract: Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: January 28, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Patrick Harran, James H. Frederich, Gordon Shore, Mai Nguyen
  • Publication number: 20190040044
    Abstract: Provided herein are Mcl-1 antagonist compositions and methods of treating cancer using the compositions described herein.
    Type: Application
    Filed: July 3, 2018
    Publication date: February 7, 2019
    Inventors: Patrick Harran, James H. Frederich, Gordon Shore, Mai Nguyen
  • Patent number: 10040780
    Abstract: Provided herein are Mcl-1 antagonist compositions and methods of treating g the compositions described herein.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: August 7, 2018
    Assignees: The Regents of the University of California, The Royal Institute for the Advancement of Learning/McGill University
    Inventors: Patrick Harran, James H. Frederich, Gordon Shore, Mai Nguyen
  • Publication number: 20170066747
    Abstract: Provided herein are Mcl-1 antagonist compositions and methods of treating g the compositions described herein.
    Type: Application
    Filed: March 3, 2015
    Publication date: March 9, 2017
    Inventors: Patrick Harran, James H. Frederich, Gordon Shore, Mai Nguyen
  • Patent number: 7622289
    Abstract: Ornithine ?-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. An N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a Ran-dependent spindle-assembly activity. Methods and compositions for inhibiting mitotic spindle assembly in a cell by specifically inhibiting OAT, and methods for screening for inhibitors of (1) the spindle-assembly function of OAT, (2) the protease that N-truncates OAT, (3) the OAT/RanGTP association and (4) the OAT/Eg5 association are disclosed.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: November 24, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrick Harran, Xiaodong Wang, Gelin Wang
  • Publication number: 20070287679
    Abstract: Ornithine ?-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a Ran-dependent spindle-assembly activity. Methods and compositions for inhibiting mitotic spindle assembly in a cell by specifically inhibiting OAT, and methods for screening for inhibitors of (1) the spindle-assembly function of OAT, (2) the protease that N-truncates OAT, (3) the OAT/RanGTP association and (4) the OAT/Eg5 association are disclosed.
    Type: Application
    Filed: June 12, 2006
    Publication date: December 13, 2007
    Inventors: Patrick Harran, Xiaodong Wang, Gelin Wang
  • Publication number: 20070149583
    Abstract: A specific diazonamide A analog and its salts and conjugates are effective in treating proliferative diseases.
    Type: Application
    Filed: October 31, 2006
    Publication date: June 28, 2007
    Inventors: Patrick Harran, Noelle Williams, Anthony Burgett
  • Publication number: 20060089397
    Abstract: The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.
    Type: Application
    Filed: October 31, 2005
    Publication date: April 27, 2006
    Inventors: Patrick Harran, Jing Li, Susan Jeong
  • Publication number: 20050197403
    Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
    Type: Application
    Filed: March 1, 2005
    Publication date: September 8, 2005
    Inventors: Patrick Harran, Xiaodong Wang, Jef De Brabander, Lin Li, Ranny Thomas, Hidetaka Suzuki